Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients
Fu-Chao Liu,1,2,* Huan-Tang Lin,1,2,* Jr-Rung Lin,1–3 Huang-Ping Yu1,2 1Department of Anesthesiology, Chang Gung Memorial Hospital, 2College of Medicine, 3Clinical Informatics and Medical Statistics Research Center and Graduate Institute of Clinical Medicine, Chang Gung Universit...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-08-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/impact-of-immunosuppressant-therapy-on-new-onset-diabetes-in-liver-tra-peer-reviewed-article-TCRM |
id |
doaj-2eb01fd8c553406a83c4267c0da99e5b |
---|---|
record_format |
Article |
spelling |
doaj-2eb01fd8c553406a83c4267c0da99e5b2020-11-24T20:53:01ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2017-08-01Volume 131043105134316Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipientsLiu FCLin HTLin JRYu HPFu-Chao Liu,1,2,* Huan-Tang Lin,1,2,* Jr-Rung Lin,1–3 Huang-Ping Yu1,2 1Department of Anesthesiology, Chang Gung Memorial Hospital, 2College of Medicine, 3Clinical Informatics and Medical Statistics Research Center and Graduate Institute of Clinical Medicine, Chang Gung University, Taoyuan, Taiwan *These authors contributed equally to this work Abstract: This nationwide, population-based study aimed to clarify the effects of immunosuppressive regimens on new-onset diabetes after liver transplantation (NODALT). The National Health Insurance database of Taiwan was explored for patients who received liver transplantation without pre-transplant diabetes from 1998 to 2012. Information regarding clinical conditions and immunosuppressant utilization among these patients was analyzed statistically. Of the 2,140 patients included in our study, 189 (8.8%) developed NODALT. The pre-transplant risk factors for NODALT were identified as old age, male sex, hepatitis C, alcoholic hepatitis, and immunosuppressant use of tacrolimus (TAC). All patients used corticosteroids as a baseline immunosuppressant. The immunosuppressant regimen of cyclosporine (CsA)+TAC+mycophenolate mofetil (MMF) contributed most to NODALT (adjusted hazard ratio 7.596) in comparison with the regimens of TAC+MMF and CsA+MMF; this regimen also contributed significantly to higher post-transplant bacteremia, urinary tract infection, pneumonia, renal failure, and mortality rate. In conclusion, our analysis confirmed TAC-based immunosuppression contributes to higher NODALT incidence than CsA-based regimen, and TAC-CsA conversion due to any causes might lead to worse clinical outcomes. Clinicians should make better risk stratifications before prescribing immunosuppressants for liver transplant recipients. Keywords: new-onset diabetes, liver transplantation, immunosuppressant, population-based study, clinical outcomehttps://www.dovepress.com/impact-of-immunosuppressant-therapy-on-new-onset-diabetes-in-liver-tra-peer-reviewed-article-TCRMNew-onset diabetesLiver transplantationImmunosuppressant |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liu FC Lin HT Lin JR Yu HP |
spellingShingle |
Liu FC Lin HT Lin JR Yu HP Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients Therapeutics and Clinical Risk Management New-onset diabetes Liver transplantation Immunosuppressant |
author_facet |
Liu FC Lin HT Lin JR Yu HP |
author_sort |
Liu FC |
title |
Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients |
title_short |
Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients |
title_full |
Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients |
title_fullStr |
Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients |
title_full_unstemmed |
Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients |
title_sort |
impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients |
publisher |
Dove Medical Press |
series |
Therapeutics and Clinical Risk Management |
issn |
1178-203X |
publishDate |
2017-08-01 |
description |
Fu-Chao Liu,1,2,* Huan-Tang Lin,1,2,* Jr-Rung Lin,1–3 Huang-Ping Yu1,2 1Department of Anesthesiology, Chang Gung Memorial Hospital, 2College of Medicine, 3Clinical Informatics and Medical Statistics Research Center and Graduate Institute of Clinical Medicine, Chang Gung University, Taoyuan, Taiwan *These authors contributed equally to this work Abstract: This nationwide, population-based study aimed to clarify the effects of immunosuppressive regimens on new-onset diabetes after liver transplantation (NODALT). The National Health Insurance database of Taiwan was explored for patients who received liver transplantation without pre-transplant diabetes from 1998 to 2012. Information regarding clinical conditions and immunosuppressant utilization among these patients was analyzed statistically. Of the 2,140 patients included in our study, 189 (8.8%) developed NODALT. The pre-transplant risk factors for NODALT were identified as old age, male sex, hepatitis C, alcoholic hepatitis, and immunosuppressant use of tacrolimus (TAC). All patients used corticosteroids as a baseline immunosuppressant. The immunosuppressant regimen of cyclosporine (CsA)+TAC+mycophenolate mofetil (MMF) contributed most to NODALT (adjusted hazard ratio 7.596) in comparison with the regimens of TAC+MMF and CsA+MMF; this regimen also contributed significantly to higher post-transplant bacteremia, urinary tract infection, pneumonia, renal failure, and mortality rate. In conclusion, our analysis confirmed TAC-based immunosuppression contributes to higher NODALT incidence than CsA-based regimen, and TAC-CsA conversion due to any causes might lead to worse clinical outcomes. Clinicians should make better risk stratifications before prescribing immunosuppressants for liver transplant recipients. Keywords: new-onset diabetes, liver transplantation, immunosuppressant, population-based study, clinical outcome |
topic |
New-onset diabetes Liver transplantation Immunosuppressant |
url |
https://www.dovepress.com/impact-of-immunosuppressant-therapy-on-new-onset-diabetes-in-liver-tra-peer-reviewed-article-TCRM |
work_keys_str_mv |
AT liufc impactofimmunosuppressanttherapyonnewonsetdiabetesinlivertransplantrecipients AT linht impactofimmunosuppressanttherapyonnewonsetdiabetesinlivertransplantrecipients AT linjr impactofimmunosuppressanttherapyonnewonsetdiabetesinlivertransplantrecipients AT yuhp impactofimmunosuppressanttherapyonnewonsetdiabetesinlivertransplantrecipients |
_version_ |
1716798330793623552 |